JP7079794B2 - アミノピリジン化合物ならびにその調製および使用のための方法 - Google Patents

アミノピリジン化合物ならびにその調製および使用のための方法 Download PDF

Info

Publication number
JP7079794B2
JP7079794B2 JP2019561849A JP2019561849A JP7079794B2 JP 7079794 B2 JP7079794 B2 JP 7079794B2 JP 2019561849 A JP2019561849 A JP 2019561849A JP 2019561849 A JP2019561849 A JP 2019561849A JP 7079794 B2 JP7079794 B2 JP 7079794B2
Authority
JP
Japan
Prior art keywords
compound
group
mmol
pharmaceutically acceptable
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2019561849A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020519606A (ja
JP2020519606A5 (https=
Inventor
キャシー シー． リンチ，
アンドレイ コンラディ，
ロバート エー． ジュニア ガレモ，
Original Assignee
コーテクシーミー， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コーテクシーミー， インコーポレイテッド filed Critical コーテクシーミー， インコーポレイテッド
Publication of JP2020519606A publication Critical patent/JP2020519606A/ja
Publication of JP2020519606A5 publication Critical patent/JP2020519606A5/ja
Priority to JP2022083544A priority Critical patent/JP2022110138A/ja
Application granted granted Critical
Publication of JP7079794B2 publication Critical patent/JP7079794B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
JP2019561849A 2017-05-10 2018-05-10 アミノピリジン化合物ならびにその調製および使用のための方法 Expired - Fee Related JP7079794B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022083544A JP2022110138A (ja) 2017-05-10 2022-05-23 アミノピリジン化合物ならびにその調製および使用のための方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762504442P 2017-05-10 2017-05-10
US201762504480P 2017-05-10 2017-05-10
US62/504,442 2017-05-10
US62/504,480 2017-05-10
PCT/US2018/032139 WO2018209132A1 (en) 2017-05-10 2018-05-10 Aminopyridine compounds and methods for the preparation and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022083544A Division JP2022110138A (ja) 2017-05-10 2022-05-23 アミノピリジン化合物ならびにその調製および使用のための方法

Publications (3)

Publication Number Publication Date
JP2020519606A JP2020519606A (ja) 2020-07-02
JP2020519606A5 JP2020519606A5 (https=) 2021-07-26
JP7079794B2 true JP7079794B2 (ja) 2022-06-02

Family

ID=64104973

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019561849A Expired - Fee Related JP7079794B2 (ja) 2017-05-10 2018-05-10 アミノピリジン化合物ならびにその調製および使用のための方法
JP2022083544A Withdrawn JP2022110138A (ja) 2017-05-10 2022-05-23 アミノピリジン化合物ならびにその調製および使用のための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022083544A Withdrawn JP2022110138A (ja) 2017-05-10 2022-05-23 アミノピリジン化合物ならびにその調製および使用のための方法

Country Status (7)

Country Link
US (2) US11059786B2 (https=)
EP (1) EP3621613A4 (https=)
JP (2) JP7079794B2 (https=)
CN (1) CN110944637A (https=)
AU (1) AU2018265397A1 (https=)
CA (1) CA3062855A1 (https=)
WO (1) WO2018209132A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US12533312B2 (en) 2011-02-04 2026-01-27 Seed Health, Inc. Method and system for preventing sore throat in humans
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11642382B2 (en) 2013-12-20 2023-05-09 Seed Health, Inc. Method for treating an individual suffering from bladder cancer
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11672835B2 (en) 2013-12-20 2023-06-13 Seed Health, Inc. Method for treating individuals having cancer and who are receiving cancer immunotherapy
US11529379B2 (en) 2013-12-20 2022-12-20 Seed Health, Inc. Method and system for reducing the likelihood of developing colorectal cancer in an individual human being
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US12318377B2 (en) 2013-12-20 2025-06-03 Seed Health, Inc. Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
CN109983012B (zh) 2016-09-16 2023-12-01 莱特豪斯制药公司 赖氨酸牙龈蛋白酶的酮抑制剂
CN110944637A (zh) * 2017-05-10 2020-03-31 库特克希米公司 氨基吡啶化合物及其制备方法和使用方法
CN115850094B (zh) * 2022-09-07 2025-02-11 北华航天工业学院 一种利用1,2-环氧丁烷合成β-氨基醇的方法
AU2023410062A1 (en) * 2022-12-22 2025-08-07 Protekt Therapeutics Ltd. Pyrrolopyridine and pyrrolopyridazine based compounds and use thereof as pkr inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016046530A1 (en) 2014-09-23 2016-03-31 Mission Therapeutics Ltd Novel compounds
WO2016057413A2 (en) 2014-10-06 2016-04-14 Cortexyme, Inc. Inhibitors of lysine gingipain
JP2016523822A (ja) 2013-05-01 2016-08-12 ネオクリ ピーティーワイ リミテッド 感染を処置する化合物及び方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20012722A3 (cs) * 1999-01-27 2002-08-14 Ortho-Mcneil Pharmaceutical, Inc. Peptidylové heterocyklické ketony pouľitelné jako inhibitory typtasy
WO2000053172A1 (en) * 1999-03-08 2000-09-14 Smithkline Beecham Corporation Ccr-3 receptor antagonists
WO2015095780A1 (en) * 2013-12-20 2015-06-25 The University Of Kansas Toll-like receptor 8 agonists
US20170014468A1 (en) * 2014-04-29 2017-01-19 Cortexyme, Inc. Methods of use for therapeutics targeting the pathogen porphyromonas gingivalis
CN108602787A (zh) 2015-11-09 2018-09-28 库特克希米公司 精氨酸牙龈卟啉菌蛋白酶的抑制剂
CN109983012B (zh) 2016-09-16 2023-12-01 莱特豪斯制药公司 赖氨酸牙龈蛋白酶的酮抑制剂
CN110944637A (zh) * 2017-05-10 2020-03-31 库特克希米公司 氨基吡啶化合物及其制备方法和使用方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016523822A (ja) 2013-05-01 2016-08-12 ネオクリ ピーティーワイ リミテッド 感染を処置する化合物及び方法
WO2016046530A1 (en) 2014-09-23 2016-03-31 Mission Therapeutics Ltd Novel compounds
WO2016057413A2 (en) 2014-10-06 2016-04-14 Cortexyme, Inc. Inhibitors of lysine gingipain

Also Published As

Publication number Publication date
CN110944637A (zh) 2020-03-31
WO2018209132A1 (en) 2018-11-15
JP2020519606A (ja) 2020-07-02
EP3621613A1 (en) 2020-03-18
US20210340105A1 (en) 2021-11-04
JP2022110138A (ja) 2022-07-28
AU2018265397A1 (en) 2019-11-28
US20200148642A1 (en) 2020-05-14
EP3621613A4 (en) 2020-12-02
CA3062855A1 (en) 2018-11-15
US11059786B2 (en) 2021-07-13

Similar Documents

Publication Publication Date Title
JP7079794B2 (ja) アミノピリジン化合物ならびにその調製および使用のための方法
AU2020233650B2 (en) Riluzole prodrugs and their use
CN111848615B (zh) 吡啶酮衍生物及包含其的抗流感病毒药物组合物
JP6622824B2 (ja) キヌレニン−３−モノオキシゲナーゼインヒビターおよびその医薬組成物ならびにこれらの使用方法
US12110263B2 (en) Ketone inhibitors of lysine gingipain
KR20190129968A (ko) 기생충성 질환의 치료를 위한 화합물 및 방법
JP2023513373A (ja) Ｐ２ｘ３修飾薬
TW202400606A (zh) 中環或大環之經苄基取代之雜環衍生物及相關用途
JP6236439B2 (ja) ヘテロアリール化合物及びその使用方法
JP2021534246A (ja) １，３，４，９−テトラヒドロ−２ｈ−ピリド［３，４−ｂ］インドール誘導体化合物及びその使用
JP7624745B2 (ja) Ｔｒｐｖ４受容体リガンド
JP2022526897A (ja) アルギニンジンジパイン阻害剤
RU2793122C2 (ru) Соединения и способы лечения паразитарных заболеваний
US20220204457A1 (en) Arginine gingipain inhibitors

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20201211

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210507

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210507

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220310

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220323

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220420

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220523

R150 Certificate of patent or registration of utility model

Ref document number: 7079794

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees